Cover Image
市場調查報告書

Gliclazide的中國市場

Investigation Report on China Gliclazide Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 334100
出版日期 內容資訊 英文 30 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Gliclazide的中國市場 Investigation Report on China Gliclazide Market, 2010-2019
出版日期: 2015年07月02日 內容資訊: 英文 30 Pages
簡介

中國的Gliclazide銷售額從2005年到2014年以12%的年複合成長率擴大,到2014年達成了1億3700萬人民幣的規模。

本報告提供中國的Gliclazide市場相關調查,提供您Gliclazide的功用·效果,中國市場上的專利及核准狀況,銷售額·銷售量的變化與預測,價格趨勢,並彙整主要製造商與市場佔有率,競爭環境及其展望,主要製造商簡介等資料。

第1章 Gliclazide的相關概念

  • 適應
  • 全球市場的銷售情形

第2章 中國的Gliclazide的市場簡介

  • 專利情形
  • 主要製藥公司
  • 市場規模

第3章 中國的Gliclazide銷售情形調查

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售數

第4章 中國的Gliclazide的主要製藥公司市場佔有率調查

  • 以銷售額為準的市場佔有率
  • 以銷售量為準的市場佔有率

第5章 中國的Gliclazide劑型的相關調查

  • 各劑型的市場佔有率:以銷售額為準
  • 各劑型的市場佔有率:以銷售量為準

第6章 中國的醫院的Gliclazide的標準價格

  • Servier (Tianjin) Pharmaceutical Co., Ltd (商品名:Diamicron)
  • Servier (France)
  • Tianjin Huajin Pharmaceutical Co., Ltd
  • Helioeast
  • Beijing Wansheng Pharmaceutical Co., Ltd
  • Guilin Hwasun Pharmaceutical Co., Ltd
  • GuoGuang

第7章 中國市場中Gliclazide的主要製藥公司

  • Servier (Tianjin) Pharmaceutical Co., Ltd
  • Servier (France)
  • Tianjin Huajin Pharmaceutical Co., Ltd
  • NanChang Helioeast Pharmaceutical Co.,Ltd
  • Beijing Wansheng Pharmaceutical Co., Ltd

第8章 中國的Gliclazide的市場預測

  • 市場規模的預測
  • 競爭情形的預測
目錄
Product Code: 1507261

According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.

As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.

First developed by Servier (France), gliclazide entered China in 1985. Gliclazide acts in a mild way and since it can inhibit platelet aggregation and thrombosis as well as lower blood viscosity, it both reduces blood glucose and prevents microangiopathy. Before Servier (France) developed gliclazide sustained-release tablet which should be given at a dose of 30 mg once daily in Nov. 2000 only gliclazide immediate-release tablet, a 80 mg formulation that should be taken in two divided doses daily, was available in the market.

Although over ten local enterprises got the approval to produce gliclazide, they all took up a small market share, among which Servier (Tianjin) Pharmaceutical Co., Ltd ranked first despite a share of less than 2% due to the support from Servier (France) that began to cooperate with it in 1987 to produce gliclazide sustained release tablet.

According to CRI's market survey, in 2014, Servier (France) and its subsidiary Servier (Tianjin) Pharmaceutical Co., Ltd took up a market share of about 96% for sales value in China while other companies like Tianjin Huajin Pharmaceutical Co., Ltd, Helioeast and Beijing Wansheng Pharmaceutical Co., Ltd shared the rest market share. The sales value of gliclazide was about CNY 137 million in 2014 and CAGR reached 12% during the period of 2005-2014.

The market size of gliclazide is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

  • market size of gliclazide in China
  • major manufacturers of gliclazide for Chinese market and their market share
  • retail price of gliclazide in Chinese market
  • market outlook of gliclazide in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-diabetic drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Gliclazide

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Gliclazide in China

  • 2.1. Patent Status
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Gliclazide in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Gliclazide in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Gliclazide in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Gliclazide in Chinese Hospitals in 2014

  • 6.1. Servier (Tianjin) Pharmaceutical Co., Ltd (Trade Name: Diamicron)
  • 6.2. Servier (France)
  • 6.3. Tianjin Huajin Pharmaceutical Co., Ltd
  • 6.4. Helioeast
  • 6.5. Beijing Wansheng Pharmaceutical Co., Ltd
  • 6.6. Guilin Hwasun Pharmaceutical Co., Ltd
  • 6.7. GuoGuang

7. Major Manufacturers of Gliclazide in Chinese Market, 2010-2014

  • 7.1. Servier (Tianjin) Pharmaceutical Co., Ltd
  • 7.2. Servier (France)
  • 7.3. Tianjin Huajin Pharmaceutical Co., Ltd
  • 7.4. NanChang Helioeast Pharmaceutical Co.,Ltd
  • 7.5. Beijing Wansheng Pharmaceutical Co., Ltd

8. Market Outlook of Gliclazide in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Registration Information of Gliclazide in China
  • Chart Approval Status of Gliclazide in China
  • Chart Sales Status of Gliclazide in China, 2010-2014
  • Chart Sales Value of Gliclazide in China, 2010-2014
  • Chart Sales Value of Gliclazide by Regions in China, 2010-2014
  • Chart Sales Value of Gliclazide Tablets in China, 2010-2014
  • Chart Sales Value of Gliclazide Capsules in China, 2010-2014
  • Chart Market Share of Major Manufacturers of Gliclazide for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Servier (France), 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd, 2010-2014
  • Chart Sales Value and Market Share of Gliclazide Made by Helioeast, 2010-2014
  • Chart Price of Gliclazide Made by Servier (Tianjin) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Tianjin Huajin Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Servier (France) in Some Chinese Cities in 2014
  • Chart Price of Gliclazide Made by Helioeast in Some Chinese Cities in 2014
Back to Top